Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

SNGX

Soligenix Inc

Dec 07 • 04:00PM ET

0.7350

Dollar change -0.0850
Percentage change -10.37	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.04	Insider Own	0.37%	Shs Outstand	10.38M	Perf Week	-25.02%
Market Cap	7.63M	Forward P/E	-	EPS next Y	-0.75	Insider Trans	0.00%	Shs Float	10.34M	Perf Month	56.38%
Income	-8.07M	PEG	-	EPS next Q	-0.20	Inst Own	8.68%	Short Float / Ratio	0.52% / 0.03	Perf Quarter	47.00%
Sales	0.20M	P/S	38.15	EPS this Y	82.74%	Inst Trans	-8.03%	Short Interest	0.05M	Perf Half Y	-0.01%
Book/sh	0.41	P/B	1.81	EPS next Y	9.64%	ROA	-55.21%	Target Price	3.00	Perf Year	-90.93%
Cash/sh	0.99	P/C	0.74	EPS next 5Y	1.00%	ROE	-307.41%	52W Range	0.38 - 10.35	Perf YTD	-89.16%
Dividend	-	P/FCF	-	EPS past 5Y	22.69%	ROI	-139.66%	52W High	-92.90%	Beta	1.87
Dividend %	-	Quick Ratio	1.99	Sales past 5Y	93.09%	Gross Margin	-232.18%	52W Low	93.42%	ATR	0.16
Employees	15	Current Ratio	1.99	Sales Q/Q	-	Oper. Margin	-4949.44%	RSI (14)	60.01	Volatility	24.83% 25.26%
Optionable	No	Debt/Eq	0.75	EPS Q/Q	86.09%	Profit Margin	-4037.19%	Rel Volume	0.74	Prev Close	0.82
Shortable	Yes	LT Debt/Eq	0.37	Earnings	Nov 13 BMO	Payout	-	Avg Volume	1.80M	Price	0.74
Recom	1.00	SMA20	44.25%	SMA50	41.54%	SMA200	-27.15%	Volume	1,333,058	Change	-10.37%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-28-20	Downgrade	Dawson James	Buy → Neutral
Jan-31-18	Downgrade	H.C. Wainwright	Buy → Neutral	$5.50 → $2.70
Aug-14-17	Reiterated	Maxim Group	Buy	$4 → $5
Jul-17-17	Initiated	H.C. Wainwright	Buy	$11

Dec-01-23 07:30AM	'HyBryte Use in Early-Stage Cutaneous T-Cell Lymphoma' Published in Frontiers in Drug Discovery (PR Newswire) -25.53%
Nov-30-23 11:07AM	Why Is Soligenix (SNGX) Stock Up 285% Today? (InvestorPlace) +135.97%
07:30AM	Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulcers in Behet's Disease (PR Newswire)
07:30AM	Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulcers in Behçet's Disease (PR Newswire)
Nov-17-23 04:00PM	Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting (PR Newswire)
08:12AM	Loading…
Nov-13-23 08:12AM	Soligenix Q3 Loss Narrows (RTT News)
07:30AM	Soligenix Announces Recent Accomplishments And Third Quarter 2023 Financial Results (PR Newswire)
Oct-20-23 04:00PM	Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting (PR Newswire)
09:00AM	ASP Isotopes and Soligenix Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV (ACCESSWIRE)
Oct-16-23 07:30AM	Soligenix to Present at The ThinkEquity Conference (PR Newswire)
Oct-13-23 09:00AM	SPI Energy and Soligenix Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV (ACCESSWIRE)
Oct-06-23 09:00AM	Knightscope, Soligenix, and Genetic Technologies Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV (ACCESSWIRE)
Sep-25-23 07:30AM	Soligenix Announces Achievement of Two-Year Stability with Bivalent and Trivalent Thermostabilized Filovirus Vaccines when Stored at High Temperatures (PR Newswire)
Sep-22-23 04:00PM	Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting and Additional Proposal to be Considered by Stockholders (PR Newswire) +5.58%
Aug-24-23 05:30AM	SNGX: HyBryte Expanded Treatment Trial Underway (Zacks)
07:30AM	Loading…
Aug-21-23 07:30AM	Soligenix Announces Recent Accomplishments And Second Quarter 2023 Financial Results (PR Newswire)
Aug-11-23 10:05AM	BioVie and Soligenix Interviews to Air on the RedChip Money Report(R) on Bloomberg TV (ACCESSWIRE)
Aug-10-23 07:30AM	HyBryte Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens Enrollment (PR Newswire)
Jul-19-23 07:13AM	SNGX: Expanding SGX302 Phase 2a Study in Psoriasis (Zacks)
Jul-11-23 07:30AM	Soligenix Announces Expansion of SGX302 (Synthetic Hypericin) Phase 2a Study in Mild-to-Moderate Psoriasis (PR Newswire)
Jun-29-23 08:07AM	Soligenix, Inc. CEO is Featured in an Interview with SmallCaps Daily (NewMediaWire)
Jun-02-23 09:00AM	Soligenix, and Graphex Group Interviews to Air on Bloomberg TV on the RedChip Money Report(R) (ACCESSWIRE)
May-30-23 05:00AM	SNGX: Positive Results for Compatibility Study of HyBryte in CTCL (Zacks Small Cap Research)
May-16-23 07:30AM	Soligenix Announces European Patent Grant for Use of Dusquetide in Oral Mucositis (PR Newswire) -6.02%
May-15-23 07:30AM	Soligenix Announces Recent Accomplishments And First Quarter 2023 Financial Results (PR Newswire) +6.85%
May-11-23 07:30AM	Soligenix Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte in the Treatment of Cutaneous T-Cell Lymphoma (PR Newswire) -5.68%
May-09-23 04:05PM	Soligenix Announces Closing of $8.5 Million Public Offering (PR Newswire) -12.57%
May-05-23 09:05AM	Soligenix Announces Pricing of $8.5 Million Public Offering (PR Newswire) -51.75%
May-04-23 03:54PM	Why Are Soligenix Shares Trading Higher Today (Benzinga) +60.56%
07:30AM	Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte in the Treatment of Cutaneous T-Cell Lymphoma (PR Newswire)
07:30AM	Loading…
May-03-23 07:30AM	Soligenix Announces Appointment of Timothy R. Coté, M.D. to its Board of Directors (PR Newswire) -11.26%
May-01-23 07:30AM	Soligenix Enters into Exclusive Option Agreement with Silk Road Therapeutics for Rights to Topical Pentoxifylline Designed to Treat Behçet's Disease (PR Newswire) +9.74%
Apr-24-23 09:18AM	SNGX: Planning for Second Phase 3 Study for HyBryte in CTCL (Zacks Small Cap Research)
07:30AM	Soligenix Submits Type A Meeting Request to U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte in the Treatment of Cutaneous T-Cell Lymphoma (PR Newswire)
Apr-14-23 01:39PM	FDA Asks For Additional Successful Trial To Approve Soligenix's Rare Cancer Candidate (Benzinga)
07:30AM	Soligenix Provides Regulatory Update on HyBryte (PR Newswire)
Apr-05-23 07:30AM	Soligenix Receives USAN Approval for "Hypericin Sodium" as Nonproprietary Name for Novel Active Ingredient in HyBryte and SGX302 (PR Newswire)
Apr-03-23 11:11AM	SNGX: Meeting with FDA to Discuss Refusal to File Letter (Zacks Small Cap Research)
07:30AM	Soligenix Announces Scheduling of Type A Meeting with the U.S. FDA for HyBryte New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma (PR Newswire)
Mar-31-23 07:30AM	Soligenix Announces Recent Accomplishments And Year-End 2022 Financial Results (PR Newswire)
Mar-09-23 07:30AM	Soligenix Submits Type A Meeting Request to U.S. FDA for HyBryte New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma (PR Newswire) +6.62%
Feb-16-23 11:54AM	Soligenix, Inc: Vital Vaccine Development Program has Potential to Address Future Marburg Virus Outbreaks (NewMediaWire)
Feb-14-23 09:55AM	Why Are Soligenix Shares Plummeting Today? (Benzinga) -18.10%
07:59AM	UPDATE 1-U.S. FDA declines to review Soligenix's cancer drug (Reuters)
07:30AM	Soligenix Receives Refusal to File Letter from U.S. FDA for HyBryte New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma (PR Newswire)
Feb-09-23 07:30AM	Soligenix Announces Reverse Stock Split (PR Newswire) -13.02%
Jan-19-23 07:30AM	Soligenix Invited to Present at the Virtual Investor Summit Event (PR Newswire)
Jan-12-23 08:30AM	Soligenix On Track to Deliver Important Front-Line Treatment to US Market in 2024 (NewMediaWire)
Jan-09-23 05:36AM	SNGX: Seeking Potential Reverse Stock Split (Zacks Small Cap Research)
Dec-23-22 04:01PM	Soligenix Announces Distribution of Series D Preferred Stock to Holders of its Common Stock (PR Newswire)
Dec-20-22 08:30AM	Soligenix Delivers Two Pivotal Milestones (NewMediaWire)
07:30AM	Soligenix Announces Publication Demonstrating Positive Correlates of Protection with RiVax® in Non-Human Primate Survival after Ricin Challenge (PR Newswire)
Dec-19-22 07:30AM	Soligenix Initiates Phase 2 Clinical Trial of SGX302 (synthetic hypericin) for the Treatment of Mild-to-Moderate Psoriasis (PR Newswire)
Dec-16-22 12:09PM	7 Stocks to Add to Your 10x Watchlist (InvestorPlace)
05:52AM	SNGX: HyBryte NDA Submitted (Zacks Small Cap Research)
Dec-15-22 07:30AM	Soligenix Announces Submission of New Drug Application to the FDA for HyBryte in the Treatment of Cutaneous T-cell Lymphoma (PR Newswire) +13.48%
Dec-06-22 08:30AM	Soligenix Positioned for Growth: Late-stage Pipeline and Key Q4 Milestones (NewMediaWire) -5.43%
Nov-16-22 10:28AM	UPDATE: Soligenix, Inc. to Showcase 2022 Milestones in Business Update Fireside Chat with PCG Advisory (NewMediaWire)
07:00AM	Soligenix, Inc. to Showcase 2022 Milestones in Business Update Fireside Chat With PCG Advisory (NewMediaWire)
Nov-15-22 07:30AM	Soligenix to Receive $1.2 M in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program (PR Newswire) -6.80%
Nov-14-22 05:39AM	SNGX: HyBryte NDA to be Submitted Before the End of 2022 (Zacks Small Cap Research)
Nov-13-22 07:12AM	Soligenix Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
Nov-11-22 09:30AM	Investor Summit Group Announces Soligenix, Inc. To Present at Q4 Conference (Newsfile)
Nov-10-22 07:30AM	Soligenix Announces Recent Accomplishments And Third Quarter 2022 Financial Results (PR Newswire)
Nov-07-22 09:30AM	New to The Street Announces Five Corporate Interviews on Episode #404, Airing on the Fox Business Network, Tonight, Monday, November 7, 2022, at 10:30 PM PT (GlobeNewswire)
Oct-28-22 06:45AM	SNGX: Invited to Submit BARDA Contract Proposal for Filovirus Vaccines (Zacks Small Cap Research)
Oct-27-22 07:30AM	Soligenix Invited to Submit BARDA Contract Proposal for Development of Thermostabilized Subunit Vaccines for Sudan Ebola and Marburg Viruses (PR Newswire)
Oct-25-22 07:30AM	Soligenix Announces Formation of Psoriasis Medical Advisory Board (PR Newswire)
Oct-24-22 09:30AM	New to The Street TV Announces its 399th Show, Featuring Five Corporate Interviews, Airing on the Fox Business Network, Tonight, Monday, October 24, 2022, at 10:30 PM PT (GlobeNewswire) +8.09%
Oct-21-22 09:30AM	New to The Street / Newsmax TV Announces its Nine Corporate Interviews for This Week's TV Broadcast, Episode #398, October 23, 2022, 10-11 AM ET (GlobeNewswire)
Oct-20-22 08:30AM	Soligenix Announces Adjournment of Annual Meeting and Information for Reconvened Meeting (PR Newswire)
Oct-17-22 10:16AM	UPDATE: New to The Street to Feature Soligenix Appearances on Its Syndicated Televised Outlets (GlobeNewswire) +5.44%
08:30AM	New to The Street to Feature Soligenix Appearances on Its Syndicated Televised Outlets (GlobeNewswire)
Oct-13-22 08:30AM	Soligenix Enters Q4 With Multiple Catalysts in Play (Newsfile)
Sep-23-22 07:30AM	Soligenix Announces Partial Adjournment of Annual Meeting and Information for Reconvened Annual Meeting (PR Newswire) -5.85%
Sep-12-22 08:30AM	FDA Awards $2.6 Million Grant for Expanded Study of Soligenix's Hybryte(TM) for CTCL (Newsfile)
Sep-08-22 07:30AM	Soligenix to Present at the H.C. Wainwright 24th Annual Global Investment Conference (PR Newswire)
Sep-06-22 07:30AM	U.S. Food and Drug Administration Awards $2.6 Million Orphan Products Development Grant for Expanded Study of HyBryte in the Treatment of Cutaneous T-Cell Lymphoma (PR Newswire)
Aug-22-22 09:54AM	Is Soligenix (NASDAQ:SNGX) Using Too Much Debt? (Simply Wall St.)
Aug-18-22 09:40AM	SNGX: Receives IND Clearance for Phase 2 Clinical Trial in Psoriasis (Zacks Small Cap Research) -7.14%
Aug-16-22 07:00AM	Presenting on the Emerging Growth Conference on August 17 Register Now (GlobeNewswire)
Aug-12-22 07:30AM	Soligenix Announces Recent Accomplishments And Second Quarter 2022 Financial Results (PR Newswire)
Jul-27-22 07:30AM	Soligenix Receives Agreement from FDA on Initial Pediatric Study Plan for HyBryte for the Treatment of Cutaneous T-Cell Lymphoma (PR Newswire)
Jul-26-22 09:27AM	Soligenix's HyBryte(TM) Treatment Now Within Reach for Rare Cancer Patients (Newsfile) +6.38%
Jul-25-22 09:16AM	Soligenix Partners With SERB Pharmaceuticals To Supply Ricin Antigen For Ricin Toxin Poisoning Treatment (Benzinga) +8.78%
07:30AM	Soligenix Announces Strategic Partnership with SERB Pharmaceuticals to Supply its Novel Ricin Antigen (PR Newswire)
Jul-20-22 03:16PM	Soligenix Shares Gain On HyBrytes Data From Blood Cancer Study (Benzinga) +11.06%
11:17AM	HyBryte Phase 3 FLASH Study for the Treatment of Cutaneous T-Cell Lymphoma Published in JAMA Dermatology (PR Newswire)
Jun-28-22 07:30AM	Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Synthetic Hypericin in the Treatment of Psoriasis (PR Newswire)
Jun-27-22 06:30AM	SNGX: Bivalent Filovirus Vaccine Candidate Provides 100% Protection in Non-Human Primates (Zacks Small Cap Research)
Jun-23-22 07:30AM	Soligenix Announces Successful Protection using a Bivalent Thermostabilized Filovirus Vaccine (PR Newswire)
Jun-07-22 08:30AM	Soligenix Moves Forward with Treatments for Cutaneous T-Cell Lymphoma and Psoriasis (Newsfile)
Jun-03-22 08:00AM	Celularity Appoints Industry Leader Diane Parks to its Board of Directors (GlobeNewswire) -5.45%
Jun-01-22 07:30AM	Key Binding Characteristics of Dusquetide to Important Intracellular Protein Identified (PR Newswire) -6.29%
May-23-22 07:30AM	Soligenix Receives US Patent Allowance for its Thermostabilized Vaccine Platform (PR Newswire) +10.36%
May-19-22 10:30AM	SNGX: Phase 2a Trial of SGX302 in Psoriasis to Initiate in Second Half of 2022 (Zacks Small Cap Research) +10.74%
May-18-22 07:30AM	Soligenix to Present at the H.C. Wainwright Global Investment Conference (PR Newswire)
May-13-22 07:30AM	Soligenix Announces Recent Accomplishments And First Quarter 2022 Financial Results (PR Newswire) -6.68%
Apr-19-22 07:30AM	Soligenix Receives $1.4M in Non-Dilutive Government Funding (PR Newswire)
Mar-31-22 10:36AM	SNGX: NDA Filing for HyBryte in 2022 (Zacks Small Cap Research)

Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. It operates through the Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses on the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions segment consists of active development programs for RiVax, a ricin toxin vaccine candidate, and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SNGX

Soligenix Inc

Upgrade your FINVIZ experience